About

Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease.

It’s Time to Revolutionize Medicine Again

More than 23,000 men, women and children in the U.S. die every year from antibiotic-resistant infections1 while over 4,000 Americans perish from influenza.2 In addition, over 100 million suffer from chronic pain3 and 3.9 million adults in the U.S. are diagnosed with liver disease.4 Shionogi’s mission is to supply the best possible medicines to protect the health and well-being of the patients we serve. 

 

With over 50 years of anti-infective research experience, Shionogi has helped to revolutionize the development of antibacterial and antiviral treatments. As bacteria, pathogens and other viruses adapt to resist existing treatments—causing millions of untreatable infections around the world—Shionogi is pursuing the development of novel treatments to combat this evolving threat.

 

Shionogi, both itself and through innovative alliances, is also pursuing the development of new treatments in other areas of high medical need, including inflammatory pain, neuropathic pain, Alzheimer’s disease and ADHD.

 

At Shionogi Inc., we’re intensely focused on developing and commercializing the scientific breakthroughs emerging from our research laboratories in Japan as well as discoveries of our strategic alliance partners. We couple our innovative discovery base with capabilities to advance drug candidates rapidly from lab to clinic to patient, forming, where appropriate, bold new partnerships to accelerate and amplify the availability of these new medications to patients around the world.

References

1  www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf

https://www.cdc.gov/nchs/fastats/flu.htm

3  Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press, 2011. http://books.nap.edu/openbook.php?record_id=13172&page=1

4  https://www.cdc.gov/nchs/fastats/liver-disease.htm

  • The Shionogi Group is committed to supplying the best possible medicine to protect the health and wellbeing of the patients we serve.

    Philosophy
  • We embrace and develop a culture of diversity, allowing employees to drive an ongoing collaborative and innovative work environment.
    Culture
  • Shionogi is committed to developing even better medicines and delivering them to patients in need. By constantly improving our technologies and services, we have worked to enhance the positive impact of our products on patient health.

    Transparency
  • The Shionogi Inc. leadership team has decades of combined pharmaceutical and industry experience in developing and commercializing therapeutics.
    Leadership
  • Partnering connects our in-house scientific knowledge with the expertise of leading academic centers, pharmaceutical companies and biotechs.
    Partners